Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study

BACKGROUND: No observational studies have evaluated the “real-world” effectiveness of dual bronchodilation comprising a long-acting β(2)-agonist plus a long-acting muscarinic antagonist vs that of triple therapy (long-acting β(2)-agonist plus long-acting muscarinic antagonist plus inhaled corticoste...

Descripción completa

Detalles Bibliográficos
Autores principales: Buhl, Roland, Criée, Carl-Peter, Kardos, Peter, Vogelmeier, Claus F, Kostikas, Konstantinos, Lossi, Nadine S, Worth, Heinrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113909/
https://www.ncbi.nlm.nih.gov/pubmed/30197512
http://dx.doi.org/10.2147/COPD.S169958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113909/
https://www.ncbi.nlm.nih.gov/pubmed/30197512
http://dx.doi.org/10.2147/COPD.S169958

Ejemplares similares